FULC stock news · Fulcrum Therapeutics, Inc.
Get alerts for FULC
Follow Fulcrum Therapeutics, Inc. (FULC) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for FULCFulcrum Therapeutics, Inc.: Other Events (FULC)
Good for FULCFulcrum agreed to sell early-stage HbF assets for about $7.0 million, subject to merger-related conditions. The cash is expected to increase a merger dividend, which favors Fulcrum.
Fulcrum Therapeutics, Inc. is likely to report a loss of 14 cents for each share soon.
NeutralFulcrum Therapeutics faces an analyst forecast for a 14-cent-per-share loss, but it is not a company report and adds no new business information.
All-stock merger finalized between Fulcrum Therapeutics and Slate Medicines.
NeutralFulcrum Therapeutics and Slate Medicines have announced a merger that will create a new entity focused on migraine treatments, backed by significant financing. This merger is expected to reshape the ownership structure and operational focus of both companies, with immediate implications for their stock prices.
Fulcrum Therapeutics, Inc. enters into a significant definitive agreement (FULC).
Good for FULCFulcrum Therapeutics has filed a Form 8-K detailing its entry into a material definitive agreement, which suggests potential strategic developments that could enhance its market position and financial outlook. This news is likely to attract investor interest and could lead to a positive market reaction.